

Argatroban

CAUTION: High administration Risk Rating Argatroban is used for treatment and prophylaxis of thromboembolism in patients with heparin-induced thrombocytopenia (HIT) To be prescribed only following consultation with Consultant Haematologist		
Form	Argatroban 250mg per 2.5ml vial (100mg/mL) concentrate for solution for infusion	Store below 25°C in original packaging to protect from light
Reconstitution	Already in solution Must be diluted further before administration	
Compatibility & Stability	Sodium chloride 0.9% Glucose 5%	
Administration	Continuous IV Infusion	
	- See Argatroban Prescribing, Administration and Monitoring Record - Withdraw 250 mg (2.5 ml) of the argatroban concentrate and add to 250 ml compatible fluid to give 1mg/ml solution. - The bag should be mixed by repeated inversion of the diluent bag for one minute. - Administer as a continuous infusion using a dedicated infusion line. - The maximum recommended dose is 10 microgram/kg/minute. The maximum recommended duration of treatment is 14 days. If a central venous access device is unavailable, administer via a large peripheral vein monitoring insertion site closely using a recognised phlebitis scoring tool. Re-site cannula at first signs of inflammation.	
	Percutaneous coronary intervention in Cathlab only	
	See Prescribing and Administration guideline for Argatroban in adults patients with or at risk for HIT undergoing PCI (Cath Lab only)	
Monitoring	See Argatroban Prescribing, Administration and Monitoring Record	
Acute reactions	Haemorrhage, purpura, Injection site reaction, rash, urticarial, Nausea, pyrexia, Dyspnoea, Tachycardia, atrial fibrillation, cardiac arrest, myocardial infarction, arrhythmia, Hypertension, hypotension, Dizziness, headache, syncope	
Extravasation	Argatroban has a low pH and may cause venous irritation and tissue damage in cases of extravasation.	
Additional Information	- To be prescribed only following consultation with Consultant Haematologist - Argatroban products contain ethanol (1g/2.5mL vial), an interaction with metronidazole or disulfiram cannot be excluded. - Unlicensed preparation in Ireland	

Information provided relates to Exembol® and Argatra® (Ethypharm)

Last updated 3/3/26

*This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications.
 Further information is available from Pharmacy on 22146 or 22542*